NASDAQ:MNKD - MannKind Stock Price, Forecast & News

MannKind trades on the NASDAQ under the ticker symbol "MNKD."

MannKind Co. (NASDAQ:MNKD) released its quarterly earnings results on Wednesday, November, 6th. The biopharmaceutical company reported ($0.05) earnings per share (EPS) for the quarter, beating analysts' consensus estimates of ($0.07) by $0.02. The biopharmaceutical company earned $14.60 million during the quarter, compared to analyst estimates of $15.03 million. During the same period in the prior year, the business posted ($0.16) EPS. View MannKind's Earnings History.

MannKind is scheduled to release their next quarterly earnings announcement on Tuesday, February 25th 2020. View Earnings Estimates for MannKind.

6 equities research analysts have issued 1-year price targets for MannKind's stock. Their forecasts range from $2.50 to $3.00. On average, they anticipate MannKind's stock price to reach $2.83 in the next twelve months. This suggests a possible upside of 92.7% from the stock's current price. View Analyst Price Targets for MannKind.

6 Wall Street analysts have issued "buy," "hold," and "sell" ratings for MannKind in the last year. There are currently 6 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for MannKind.

News stories about MNKD stock have been trending neutral recently, InfoTrie Sentiment reports. InfoTrie ranks the sentiment of press coverage by monitoring more than six thousand news and blog sources in real-time. The firm ranks coverage of public companies on a scale of negative five to five, with scores nearest to five being the most favorable. MannKind earned a media sentiment score of 0.4 on InfoTrie's scale. They also assigned press coverage about the biopharmaceutical company a news buzz of 0.0 out of 10, meaning that recent press coverage is extremely unlikely to have an impact on the stock's share price in the immediate future. View News Stories for MannKind.

Some companies that are related to MannKind include Amgen (AMGN), Gilead Sciences (GILD), Celgene (CELG), Vertex Pharmaceuticals (VRTX), Biogen (BIIB), Regeneron Pharmaceuticals (REGN), Alexion Pharmaceuticals (ALXN), Seattle Genetics (SGEN), Incyte (INCY), BioMarin Pharmaceutical (BMRN), Alnylam Pharmaceuticals (ALNY), EXACT Sciences (EXAS), Neurocrine Biosciences (NBIX), Ionis Pharmaceuticals (IONS) and Exelixis (EXEL).

Based on aggregate information from My MarketBeat watchlists, some companies that other MannKind investors own include Bausch Health Companies (BHC), Novavax (NVAX), ACADIA Pharmaceuticals (ACAD), Gilead Sciences (GILD), Advanced Micro Devices (AMD), Chesapeake Energy (CHK), NVIDIA (NVDA), Intel (INTC), Lexicon Pharmaceuticals (LXRX) and Opko Health (OPK).

MannKind's stock is owned by a number of of institutional and retail investors. Top institutional investors include State Street Corp (1.66%), FMR LLC (1.54%), Parkman Healthcare Partners LLC (0.69%), Charles Schwab Investment Management Inc. (0.58%), Dupont Capital Management Corp (0.29%) and Bank of New York Mellon Corp (0.25%). Company insiders that own MannKind stock include Michael Castagna, Patrick Mccauley, Roxanne S Austin, Steven B Binder and Stuart A Tross. View Institutional Ownership Trends for MannKind.

MNKD stock was sold by a variety of institutional investors in the last quarter, including Schonfeld Strategic Advisors LLC and Bank of America Corp DE. View Insider Buying and Selling for MannKind.

MNKD stock was acquired by a variety of institutional investors in the last quarter, including Parkman Healthcare Partners LLC, FMR LLC, Renaissance Technologies LLC, California Public Employees Retirement System, Dupont Capital Management Corp, State Street Corp, Sowell Financial Services LLC and Charles Schwab Investment Management Inc.. Company insiders that have bought MannKind stock in the last two years include Michael Castagna, Patrick Mccauley, Roxanne S Austin, Steven B Binder and Stuart A Tross. View Insider Buying and Selling for MannKind.

Shares of MNKD can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity and Charles Schwab.

One share of MNKD stock can currently be purchased for approximately $1.47.

MannKind has a market capitalization of $303.42 million and generates $27.86 million in revenue each year. The biopharmaceutical company earns $-86,970,000.00 in net income (profit) each year or ($0.59) on an earnings per share basis. MannKind employs 225 workers across the globe.View Additional Information About MannKind.

The official website for MannKind is http://www.mannkindcorp.com/.

MannKind's mailing address is 30930 RUSSELL RANCH ROAD SUITE 300, WESTLAKE VILLAGE CA, 91362. The biopharmaceutical company can be reached via phone at 818-661-5000 or via email at [email protected]